<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 310 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page309.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=310">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 310 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 310</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=310"><img src="../thumb/310.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Anti-Microbials - 18.12                                                        2020-04 / 273
       incr.dolutegravir plasma conc.with atazanavir/ telaprevir/atazanavir   Prophylax.of H.simplex. infects. in immunocompromis.pts:   pain/naus./vomit./elev.biochemic.mark.& discont. until diagnos.of
       + ritonavir, decr.dolutegravir conc.with tipranavir + ritonavir/ fosa-  Adults: 200 mg 4x/day. Sev. immunocomprom./imp.GI absorpt.incr.  pancreatit.excl., ren./ hepat. impairm., safety & effic.not est.in pts.
       mprenavir + ritonavir         to 400 mg 4x/day or IV ther. Treatm.durat.determin.by risk period.   with signific. underlying liv.disords./dis., monit. liv. funct.in pts.with
       LEGRAM, Novagen [P/S]         Childr.2 yrs.& old: Adult dos. Und.2 yrs: Half adult dos.(limit.data)  pre-exist.liv.dysfunct., also consult prod.lit.of concom.antiviral ther.
                                     Varicella zoster treatm: Adults: 800 mg 5x/day x7 days instit.
                                                                  for hepatit. B/C, monit.hepat.funct.for sev.mnths.aft.discont.in pts.
       Lamivudine                    ASAP.aft. rash onset. Consid.IV ther. in sev.immunocomprom./imp.  co-infect.with hepatit.B, pts.with chron. hepatit. B/C treat.with
       Indications: Part of anti-retrovir.combinat.ther.of HIV infect.  GI absorpt. Adolesc. 12-18 yrs: 800 mg 4x/day x5 days. Immuno-  antiretrovir.ther.are at incr. risk for sev.& potent.fatal hepat.adverse
       adults & childr.              comprom. childr: 20 mg/kg (not exceed. 800 mg)4x/day x5 days   reacts., eval. for signs of fat redistribut., elderly, CV risk assessm. in
       (S4) TABS, A40/20.2.8/0376    start.within 24 hrs.of rash onset. In sev.immunocomprom.childr.over   pts.with evid.of lipodystrophy, immune reconstit. inflammat.syndr.,
       710602-001: 150 mg, 60, R148,76  2 yrs. adult dos.may be given (limit.data).  seek med.advice if exper. joint pain/aches/stiffn./movem.diffic.as
       (S4) ORAL SOL, A40/20.2.8/0561. 10 mg/ml  Sev.immunocomprom.pts: Adults: 800 mg 4x/ day 6 hrly. Bone   osteonecros. poss., opportunist.infects & other HIV complic. still
       710603-001: 240 ml, R114,04   marr.recipients admin.IV aciclovir 3xdly x1 mnth.prior to oral ther.   poss., not proven to prev.HIV transmiss. through sex.cont./bld.con-
       Dosage: In combinat.with zidovudine as per PI  Treatm. durat.6-12 mnths.in advanc.HIV dis.  tam., monit. haematolog. paramet., in case of sev.anaem./ myelo-
       Adults & adolesc.over 12 yrs: 300 mg dly admin. as sngl.dly   Contraindications: Acyclovir/valaciclovir hypersens., safety in   suppress./pre-exist.bone marr.compromise where dos.adjustm.may
       dos OR 150 mg 2xdly.          pregn.& lactat.not est.      be reqd./where discont.of one of the act.necess.use separ.preps.,
       Low bm(&lt; 50 kg): Recomm.dos: 2 mg/kg 2xdly.  Side effects: Bld.dyscras., hypersens.reacts., headache, fatig., diz-  monit. concom. co-trimoxazole, avoid concom.high co-trimoxazole
       Childr.&gt; 3 mnths.-12 yrs: Recomm.dos: 4 mg/kg 2xdly. Max.dly.  zin., confus., hallucinat., trem., psychos., agitat., somnol., convuls.,   dos.in Pneumocystis carinii pneumon./ toxoplasmos., concom.phe-
       dos: 300 mg                   coma, GI disturbs., hepatit., jaund., diffuse.hair loss, ac.ren.fail.  nytoin, monit.ren.funct./ haemotolog. paramet.with concom.potent.
       Contraindications: Concom.zalcitabine, safety in pregn.& lactat.  Special precautions: Sev.ren.impairm., poss. interacts. with any   nephrotox./myelo-suppress.agents, consid. concom. prophylact.an-
       not est., limit.data in childr.und. 3 mnths.  ren.tubul.excret.med, adeq. hydrat., elderly.  timicrob.ther., concom.self-admin. med.
       Side effects: Lact.acidos.(mostly women) usual. assoc.with sev   Drug interactions: Probenecid decr.ren.clear.,  Interactions: Poss.interacts.with meds.elimin.by act. ren.secret.,
       hepatomegaly & steatos.with fatalit., pancreatit., GI disturbs., bld.  co-trimoxazole incr.plasma lev., rifampicin decr.AUC of zidovudine,
       dyscras., alopec., periph. neuropathy, paraesthes., headache, ar-  MACLEODS FAMCICLOVIR, (Activo)    lamuvidine poss. inhib.zalcitabine intracell.phosphorylat., alt. bld. lev.
       thralg., musc.disords., rhabdomyolys., malaise, fatig., fev., skin rash,   Macleods [P/S]  with phenytoin, probenecid incr.mean half-life & AUC of zidovudine.,
       liv.enzym./ser. amylase rises  Famciclovir                 stavudine intracell. phosphorylat. poss.inhib.by zidovudine, incr.incid.
       Special precautions: Poss.contin.of HIV complicat. & opportun-  Indications: Herpes zoster (shingles) infect., 1st episode genit.  of neutropen.with paracet., cert.agents incl.aspir./ codeine/ morph./
       ist.infects., ther.not proven to prev. transmiss.through sex.cont./bld.  herpes within 72 hrs.of sympts, recurr. genit.herpes within 6 hrs.  methadone/indomethac./ ketoprof./ lorazepam/oxazepam/naprox./
       contam., ren./hepat.impairm., advanc.cirrhot.liv.dis., discont. use if   of sympts, suppress. recurr.genit.herpes in immunocompet. pts.  cimetidine/ clofibrate/dapsone poss.alt. zidovudine metabol.by inhib.
       pancreat./lact.acidos./hepatotoxic. suspect., risk fact.for liv.dis.  (S4) TABS, 45/20.2.8/1157, 1158  glucoronidat./direct. inhibit. hepat.microsom.metabol.
       Drug interactions: Trimethoprim incr.plasma conc., intracell.phos-  3000669-001: 125 mg, 10, R126,50
       phorylat.of zalcitabine poss. inhibit.  3000670-001: 250 mg, 21, R552,00  MIVUTEN, Cipla Medpro [P/S]
                                     Dosage: Herpes zoster: Adults: 250 mg 3xdly.x7 days. Init.within
                                                                  Lamivudine 300 mg, tenofovir 300 mg
       LODIZ, Novagen [P/S]          72 hrs of rash onset.        Indications: Treatm.of HIV-infect.adults over 18 yrs.in combinat.
       Lamivudine 150 mg, zidovudine 300 mg  1st episode genital herpes: Within 72 hrs of appear. of   with other antiretrovir.meds.
       Indications: Part of anti-retroviral combinat.ther. for treatm.of   sympts.250 mg 3xdly.x5 days.  (S4) TABS, 45/20.2.8/0108
       HIV infect.adults & childr.over 12 yrs.with progress.immunodefic.  Recurr.genital herpes: Within 6 hrs of sympts appear., 125 mg   718676-001: 30, R200,35
       (S4) TABS, A40/20.2.8/0381    2xdly.x5 days.               Dosage: One tablet once dly.with food.
       710596-001: 60, R407,25       Suppress.recurr.genital infects.in immunocompet. pts: 125-  Contraindications: Safety & effic.not est.in hepatit. B vir.co-in-
       Dosage: Adults & childr.over 12 yrs: 1 tab. 2xdly. Consult pack-  250 mg 2xdly., treatm. durat.dep.on sever. Re-eval.treatm.aft.12   fects., mod.to sev.ren.impairm. (CrCl &lt; 50 ml/min), pregn. & breast
       age insert for separ.agents dur.combin.ther.  mnths. Max.toler. dos: Herpes zoster: 750 mg 3x/day for 7 days. Gen-  feed., childr. und.18 yrs., concom.zalcitabine
       Contraindications: Abnorm.low neutrophil counts /haemoglo-  it.herpes: 750 mg 3x dly.for 5 days & up to 500 mg 3x/day for 10 days.  Side effects: Angioed., allerg.react., bld.dyscras., hyperlactataem.,
       bin lev., insuffic.data in childr. bel.12 yrs., concom.ribavirin/sta-  Contraindications: Penciclovir hypersens., pregn. & lactat.  lact.acidos., weight loss, lipodystroph., hypophosphataem., insomn.,
       vudine, concom.IV ganciclovir/foscarnet not recomm., safety in   Side effects: Freq: Headache, dizzin., N&V, abdom. pain, diarrh.,   headache, anorex., dizzin., depress., anx., periph. neuropathy, par-
       pregn. not est., lactat.      abnorm. LFT, rash, prurit. Less freq: Thrombocytopen., angioed.,   aesth., asthen., cough, nas.sympt, dyspn., naus., abdom.cramps/
       Side effects: Bld.dyscras., pancreatit., lact. acidos.in absence of   confus., hallucinat., somnol., palpitat., cholestat.jaund., urticar.   pain, vomit., diarrh., flatul., pancreatit., incr.ser.amylase/gluc., hep-
       hypoxaem.& sev. hepatomegaly with steatos.somet.fatal, headache,   Unknown: Ser.skin reacts.incl.erythema multiforme/ Stev.-Johns.  atit., incr. trans.hepat.enzym, incr.tot. cholester./ triglycer. lev., incr.
       insomn., periph. neuropathy, malaise, fatig., musculoskelet.pain, GI   syndr./toxic epiderm. necrolys., leukocytoclast. vasculit.  creatin.kinas., elev.neutroph. count, hepat.steatos., rash, urticar.,
       disturbs., cough, nas. sympts., liv.enzym./ser.amylase incr., anaem.   Warnings and special precautions: Imp.ren. funct., sev.hepat.  prurit., sweat., alopec., arthralg., musc.disords./weakn., myalg.,
       poss. req.bld.transfus., paraesthes., asthen., skin reacts., myalg.,   impairm., transmiss.risk of genit. herpes incr.dur.ac.episod., avoid   rhabdomyolys., osteomalac./myopathy, fev., malaise, fatig., pneum.,
       fev., somnol., dizzin., sweat., dyspn., chest/gen.pain, anx., urin.freq.,   intercourse while sympt. pres., adeq protect.dur.intercourse., lact.   haematur., glycosur., hypokalaem.
       chills, CNS effs., flu-like syndr., liv.disords., myopathy, nail, skin &   intol., complicat.herpes zoster/immunocompromis. with ophthalm.  Special precautions: Pts.partic.obese women with hepatomeg-
       oral mucosa pigmentat., convuls., cerebr. events.  zoster/high risk for dis.disseminat. & viscer.organ involvem.should   aly/hepatit or other known liv.dis. & hepat.steatos.risk fact., spec.
       Special precautions: Developm.of opportunist. infects.& other   be treated with IV antivir. ther., monit.clin.effic.with concom. ralox-  risk assoc.with hepatit.C co-infect.pts.treat.with alpha-interferon &
       HIV compl.poss.cont., ther.not proven to prev.HIV transmiss.through   ifen, safety & effic.in childr.not est.  ribavirin, elderly, ren.funct.monit.prior to init. ther./ mnthly dur.1  yr.&
                                                                                            st
       sex.cont./ bld. contam., monit.haematolog.paramet., in case of sev.  Interactions: Probenecid & other drugs that aff. ren. physiol.could   quarterly thereaft.& more freq. in at risk pts., concom./rec.nephrotox.
       anaem./myelosuppress./pre-exist.bone marrow compromise where   aff.plasma lev., raloxifen may affect effic.  meds., discont. use if pancreat.suspect., discont.if find. suggest.me-
       dos.adjustm.may be reqd./where discont.of one of the act.necess.  tabol./lact.acidos./hepatotoxic., test for hepatit.B bef.init.ther., imp.
       use separ. preps., discont.ther.if pancreatit.suspect./ aminotrans-  MACLEODS LAMIVUDINE 150 & ZIDOVUDINE 300, (Activo)   liver funct., risk of rebound hepatit.B post-treatm.in pts.with adv.
       ferase lev. rapidly elev./progress. hepatomegaly/ metabol.acidos.  Macleods [P/S]  cirrhot. liv.dis.due to chron.Hepatit.B infect, mitochrond.dysfunct.
       of unknown origin, cross.placenta in animals, carcinogen.risk to hu-  Lamivudine 150 mg, zidovudine 300 mg  in HIV negat.infts.expos.in utero/post natally theref.clinic.& lab.
       mans not exclud., treatm.dur.1  trimest.of pregn. not advis., cons.be-  Indications: Part of anti-retroviral combinat.ther. for treatm.of HIV   follow-up recomm., inflamm.resp.to indol./resid. opportunist. pat-
                    st
       nef./risk dur.pregn.as zidovudine poss.reduc.matern.-foet.HIV trans-  infect.adults & childr.over 12 yrs. with progress.immunodefic., init.  hog.report.in sev.immune defic.HIV infect.pts., monit.BMD in pts.
       miss., excret.in milk of lactat.rats, ren./hepat.funct. impairm., avoid   prophylax.(until serology test results avail.) in HIV neg.adults fol-  with patholog.bone fract.hist./at risk of osteopen.where Ca & vit.D
       concom.high co-trimoxazole dos. in Pneumocystis carinii pneumon./  low. suspect./known HIV occupat.expos. Admin. of protease inhibit.  supplementat. poss benefic., Lapp lact.defic./gluc.-galact. malab-
       toxoplasmos., concom. phenytoin, monit.ren.funct./haemotolog.   recomm.when large vol.of innoculat. occurs/when source mat.has   sorpt./ heredit.galact.intol., concom. didanosine not recomm.esp.
       paramet.with concom.potent.nephrotox./myelo-suppress. agents,   high viral titre or when innoculat.occurs from pt.with HIV resist. to   where vir loads high and CD4 cell counts low, HIV transmiss.risk not
       concom.prophylact.antimicrob. ther., elderly, concom.paracet., obese   zidovudine/lamivudine.  prev., high. virologic. fail.& early emerg.resist. report. when combin.
       women with hepatomegaly, hepatit./other risk fact.for liv.dis., con-  (S4) TABS, 44/20.2.8/0591  with once dly.abacavir & didanosine regimens, concom.atazanavir
       com. self-admin.medicat., advanc.cirrhot.liv. dis.due to Hepatit.B   723893- 001: 56, R363,07  without ritonavir not recomm., discont.concom.didanosine if dida-
       infect., late-occur.vag. neoplasms in animals.  723893-002: 60, R389,00  nosine advers.effs.develop.
       Drug interactions: Co-trimoxazole incr.plasma lev., incr.incid.of   Dosage: Adults & childr.over 12 yrs: 1 tab. 2xdly. Consult pack-  Drug interactions: Ser.conc.of tenofovir &/ concom. drugs elimin.
       neutropen.with paracet., poss interact.with meds.inhibit. glucuroni-  age insert for separ.agents admin.dur.combin.ther.  by act.tubul.secret.may incr., poss.virolog.fail./resist.with concom.
       dation/ direct. inhibit.hepat.microsom.metabol., poss.incr. toxic. risk   Post expos.prophylax: Init.ther.pref.with.1-2 hrs aft. expos. Cont.  abacavir., incr. tenofov.expos.with co-admin. atazanavir, AUC & C min
       with potent nephrotox./myelosuppres.meds, ribavirin/ stavudine is   unt.confirm.of HIV status of source. Prophylact.course to be contin.for   of concom.atazanavir decr., incr.system. expos.of concom.didano-
       antagonist.in vitro, probenecid incr.mean half-life & area und.plasma   4 wks should source be confirm.as HIV pos. Dos: 1 tab 2x dly. Dos.  sine, incr.AUC & C min with darunavir/ritonavir combin., C min of con-
       conc.curve of zidovudine.     to be strict.adher.to. Discont.ther.as soon as source is confirm.not   com. emtricitabine incr, C max of concom.indinavir incr., AUC incr.with
                                     to be HIV infect. If protease inhibit.reqd.follow.loc.CDC guidelines.
       LOVIRE, Ranbaxy [P/S]         Contraindications: Abnorm.low neutrophil counts/ haemoglo-  lopinavir/ritonavir combinat., incr. lamivudine ser.conc.with concom.
                                                                  trimethoprim, intracell.phosphorylat.of concom.zalcitabine inhib., ser.
       Aciclovir.                    bin lev., mod.to sev.ren. impairm., childr.bel.12 yrs., concom.riba-  conc.incr.by agents reduc.ren.funct.
       Indications: Init.& recurr.H.simplex.infects.of skin & mucous   virin/ stavudine/ zalcitabine, concom.IV ganciclovir/ foscarnet not
       membr., init.& recurr.genit. H.simplex in immuno-comprom.& non   recomm., safety in pregn.not est., lactat.  MYLAN ACICLOVIR, (Mylan) Xixia [P/S]
       immuno-compromis.pts., suppress.of recurr.genit.H.simplex in im-  Side effects: Freq: Hyperlactat., headache, dizzin., insomn.,   Aciclovir
       munocompet. pts., prophylax.of H.simplex. infects. in immunocom-  cough, nas.sympts., naus., vomit., abdom.pain/ cramps, diarrh.,   Indications: Treatm.of init./recurr.H.simplex infects.of skin &
       promis.pts., treatm.of H.zoster. infects.if les.not old.than 72 hrs.,   skin reacts., arthralg, musculoskelet. pain, malaise, fatig., fev.,   mucous membr.incl.init./recurr. genit. H simplex virus infects.in
       treatm. of Varicella zoster within 24 hrs.of typical chickenpox les.  anaem., neutropen., leucopen., liv.enzym./bilirub.incr. Less freq:   immunocompet./ compromis.pts., suppress.of recurr.genit.H sim-
       (S4) DISPERS.TABS, 32/20.2.8/0017, 0018.  Bld.dyscras., lact.acidos.& sev. hepatomegaly with steatos.somet.  plex infects.in immunocompet. pts., H simplex infects. prophylax.
       838225-004: 200 mg, 25, R73,27  fatal., anorex., lipodystroph., periph.neuropathy/paraesthes, som-  in immunocompromis.pts., treatm.of H zoster infects.if les.not
       838233-015: 400 mg, 70, R280,53  nol., loss of ment.acuity., convuls., pancreatit, ser. amylase incr.,   old.than 72 hrs., treatm.of Varicella zoster infects.within 24 hrs.of
       Dosage: Dissolv.tabs.in 50 ml water or swallow whole.  rhabdomyolys., thrombocytopen., pancytopen., pure red cell ap-  typic. chickenpox rash.
       Init.& recurr.H.simplex.infects.of skin & mucous membr:   las., aplast. anaem., anx., depress., cardiomyop., dyspn., nail/skin   (S4) IV INFUS. 42/20.2.8/0069
       Adults: 200 mg 4 hrly.5x/day x5 days. Extend treatm.durat.in sev.  & oral mucosa pigmentat, taste disturb., dyspeps., sweat., myalg.,   703891-001: 250 mg, 5 vials, R546,25
       infects. Sev. immunocomprom./imp.GI absorpt.400 mg 5x/day or IV   myopathy, urin. freq., gynaecomast., chest/gen.pain, asthen., chills,   Dosage: Admin.by slow IV infus.over 1 hr.aft. reconst.& dilut.
       ther. Immunocomprom.childr.2 yrs.& old: Adult dos. Und.2 yrs:   influenza-like syndr.  Treatm.durat.usual.5 days.
       Half adult dos.(limit.data)   Warnings and special precautions: Pts.with risk fact.for liv.dis.,   H simplex encephalit.& neonates H simplex infects: Usu-
       Suppress.of recurr.H.simplex in immunocompet. pts: Adults:   discont.in pts.develop. lab./ clin. findings suggest.lact.acidos./hepa-  al.10 days accord.to pt.condit.& respons.
       200 mg 4x/day OR 400 mg 2x/day. In some pts.200 mg 3xdly suit.   totox., poss. mitochrond.dysfunct. infts./childr.expos.in utero theref.  H simplex- immunocompromis.pts: Adults: 5 mg/kg 8 hrly.
       Interupt.ther.periodic.to re-assess.  clinic.& lab.follow-up recomm., consid. pancreatit.if pt.devel. abdom.  Childr: 250 mg/m 8 hrly.
                                                                          2</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page309.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page305.html">305</a>&nbsp;&nbsp;&nbsp;<a href="page306.html">306</a>&nbsp;&nbsp;&nbsp;<a href="page307.html">307</a>&nbsp;&nbsp;&nbsp;<a href="page308.html">308</a>&nbsp;&nbsp;&nbsp;<a href="page309.html">309</a>&nbsp;&nbsp;&nbsp;<a href="page310.html">310</a>&nbsp;&nbsp;&nbsp;<a href="page311.html">311</a>&nbsp;&nbsp;&nbsp;<a href="page312.html">312</a>&nbsp;&nbsp;&nbsp;<a href="page313.html">313</a>&nbsp;&nbsp;&nbsp;<a href="page314.html">314</a>&nbsp;&nbsp;&nbsp;<a href="page315.html">315</a>
             </td>
             <td width="35%"><a href="page311.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page311.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
